GLP1R and type 2 diabetes mellitus: The GLP1R agonists used in treating type 2 diabetes andobesity provide cardiovascular benefits beyond glucose control, including areduction in EAT thickness and the modulation of metabolic pathways [95, 96].Notably, GLP1R is expressed in EAT but not SAT, supporting the hypothesis of adirect effect on this fat depot [97].